Treatment-Resistant Anxiety Disorders: Neurotrophic Perspectives
October 31st 2006Anxiety disorders are the most prevalent psychiatric disorders in the United States. Although effective treatments are available, such as the SSRIs and cognitive-behavioral therapy (CBT), it is estimated that in about 40% of patients, anxiety disorders are partially or completely resistant to first-line treatment.
Enlisting Family Members to Address Treatment Refusal in Substance Abusers
October 31st 2006Anyone who is close to someone who abuses alcohol or drugs knows all too well that substance abusers do not typically seek treatment until they have experienced years of substance-related problems. During the first year after onset of a diagnosable substance use disorder, only 1 of 5 alcohol-dependent persons and 1 of 4 drug-dependent persons receive treatment.
Neurotransmitters, Pharmacologic Synergy, and Clinical Strategies
October 31st 2006Although studies now suggest that some psychotropic medication regimens have a somewhat higher success rate than the one-third rule would have predicted, psychiatrists are still left with the problem of why it is that only one third to one half of patients who are treated get better, and why fewer still sustain that improvement over time
Pathology and Management of Treatment Resistance in Bipolar Disorder
October 30th 2006The problem of treatment resistance in bipolar disorder begins with its definition. Characterizing the phases of bipolar disorder as manic, mixed, hypomanic, or depressed does not do justice to the reality for many persons with this disorder.
Treatment Resistance in Schizophrenia: The Role of Alternative Therapies
October 30th 2006In 1931, Gananath Sen and Kartick Chandra Bose reported on the use of an alkaloid extract from the Rauwolfia serpentina plant in the treatment of hypertension and "insanity with violent maniacal symptoms." They noted that dosages "of 20 to 30 grains of the powder twice daily produce not only a hypnotic effect but also a reduction of blood pressure and violent symptoms
Troubleshooting Delirium in Elderly Inpatients
October 1st 2006Delirium is characterized by an altered level of consciousness, decreased attention span, acute onset, and fluctuating course. About 15% of elderly patients admitted to the hospital have delirium as a presenting or associated symptom. Delirium will develop in another 15% of elderly patients during hospitalization.
Histone Deacetlylase Inhibitors May Hold Cure for Friedreich Ataxia
October 1st 2006A team from the The Scripps Research Institute (TSRI) was able to reactivate a gene, the metabolic silencing of which is responsible for Friedreich ataxia, a rare autosomal recessive neurodegenerative disorder that leaves affected persons crippled and vulnerable to scoliosis, diabetes, and heart disease. The research team, led by Joel Gottesfeld, PhD, a professor in the Department of Molecular Biology at TSRI in La Jolla, California, set about identifying and testing compounds that inhibited histone deacetylases in lymphocytes from persons with Friedreich ataxia. They hit upon one-BML-210-that reactivated the frataxin gene.
Pet Technology Sheds Light On Tobacco Dependence
October 1st 2006Typical smokers need to have brain nicotine receptors almost completely saturated throughout the day. This need creates an almost uncontrollable urge to keep smoking, commented Nora D. Volkow, MD, director of the National Institute on Drug Abuse (NIDA), addressing a study by NIDA researchers on nicotine addiction.
Anesthetic Trumps Treatment-Resistant Depression
October 1st 2006A small group of patients with treatment-resistant major depression achieved symptom relief within hours of receiving a single low-dose intravenous infusion of ketamine. The low-dose anesthetic apparently triumphed in these patients where other treatments including oral antidepressants, which can take 8 weeks or longer to "kick in" failed.
Understanding and Treating Complex Regional Pain Syndrome
October 1st 2006The Reflex Sympathetic Dystrophy Syndrome Association estimates that the CRPS affects between 200,000 and 1.2 million Americans. The underlying causes of the syndrome have yet to be defined, and no definitive diagnostic test exists even though CRPS was first described in the late 19th century by the neurologist Silas Weir Mitchell. Mitchell referred to the cluster of symptoms he noticed in some of the Civil War soldiers who were under his care as "causalgia.
AD-Diabetes Link Hot Topic at International AD Conference
October 1st 2006A possible link between diabetes and cognitive dysfunction, specifically Alzheimer disease (AD), is becoming increasingly apparent. Indeed, compared with AD risk in healthy persons, the risk of AD development is 65% to 100% greater in persons with diabetes.
Study Confirms Pd–Pesticide Exposure Link
October 1st 2006Persons who are occupationally or otherwise regularly exposed to pesticides are at a 70% higher risk for Parkinson disease (PD) than is the general population. The findings were drawn from a subpopulation of 7864 persons who reported pesticide exposure in 1982.
The National MS Society: Support Resources for Patients, Families, and Professionals
October 1st 2006Although the prospect of disability is very real, help is available; the National Multiple Sclerosis Society provides a vast array of information and support services for patients, their families, and for health care professionals.
Intrathecal Baclofen Therapy Underused
October 1st 2006Intrathecal baclofen therapy (IBT; Lioresal) may be underused in stroke patients with spasticity, according to a new survey by the National Stroke Association. Of patients responding to the survey, 58% experienced spasticity. Of these, only half (51%) received any type of treatment for their condition.
Costs of Ischemic Stroke Projected to Rise
October 1st 2006The direct and indirect costs of ischemic stroke may exceed $2.2 trillion from 2005 to 2050 in the United States, according to research by Devin L. Brown, MD, assistant professor in the Department of Neurology at the University of Michigan, Ann Arbor, and colleagues.
Better Tools Needed to Measure Treatment Outcome
October 1st 2006The need for better tools, as well as better use of existing tools, to measure treatment response in clinical trials was a principle focus of the 46th annual NIMH-sponsored NCDEU (New Clinical Drug Evaluation Unit) meeting, held June 12-15 in Boca Raton, Fla. Improved clinical research techniques are needed to better separate treatment effect from placebo response, to distinguish between active comparators, and to facilitate development of novel treatments, according to several presenters at the conference.
NIDA Confirms Benefit of Drug Treatment Programs for Criminal Offenders
October 1st 2006Effective treatment of drug abuse and addiction in the criminal justice system saves the community money and reduces crime, the NIH's National Institute on Drug Abuse (NIDA) reported in a recently released booklet, Principles of Drug Abuse Treatment for Criminal Justice Populations.
IOM Report Takes on Medication Errors . . . Again
October 1st 2006In its latest report on medication errors, a committee assembled by the Institute of Medicine (IOM) included some sidebars on psychiatric drugs. The report, issued in July, said that there is too little data on misadministration of psychiatric drugs and that clinical trials with psychiatric drugs have been small and incapable of providing pragmatic, comparative information.
Book Review: Principles and Practice of Psychopharmacotherapy, 4th Edition
October 1st 2006A new edition of an established text is an opportunity for its authors and editors to review new information and prune what is no longer useful. The 4th edition of Principles and Practice of Psychopharmacotherapy is more successful at the former than it is at the latter.